# Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam

> **NCT02082665** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 6 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Rosuvastatin10 mg tablet
- **DRUG:** Midazolam 3 mg syrup
- **DRUG:** Dabrafenib 75 mg capsule

## Key facts

- **NCT ID:** NCT02082665
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-19
- **Primary completion:** 2016-07-01
- **Final completion:** 2016-08-01
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2017-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02082665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02082665, "Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02082665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*